Our findings suggest that the IGFBP-3 A-202C polymorphism is a potential biomarker for breast cancer risk in Palestinian women; however, further research should focus on validating these findings in larger, more diverse populations and exploring the cost-effectiveness of incorporating this polymorphism into existing screening programs. This evidence concerns the gene IGFBP3 and breast carcinoma.